---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210615"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:33:07.385758+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Therapeutics Q1 net loss $22.2M; cash $123M funds into 2028

## Summary
- Net loss of $22.2M for Q1 2026 vs net income of $73.0M in Q1 2025, which included an $87.4M gain on sale of Aadi Subsidiary.
- Cash, cash equivalents and short-term investments of $123.0M as of March 31, 2026, down from $145.7M at Dec 31, 2025; expected to fund operations into 2028.
- R&D expenses of $17.2M, including $5.3M development milestone to WuXi Biologics, up from $8.8M in Q1 2025.
- Phase 1 trials for HWK-007 and HWK-016 continue enrollment; IND for HWK-206 in small-cell lung cancer/neuroendocrine tumors on track for mid-2026.
- Initial Phase 1 data for pipeline candidates expected in the first half of 2027.

## SEC filing metadata
- accession: 0001193125-26-210615
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/0001193125-26-210615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/whwk-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210615
- JSON: https://secwatch.observer/filing/0001193125-26-210615.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210615.txt

## Source-grounded claims
- claim_id: fe7d58b080e7ea451eeca8515e713e4f4fdae55b
  claim: Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $22.2 million.
  evidence_excerpt: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/0001193125-26-210615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.